Last updated: February 23, 2026
Case Overview
Eli Lilly and Company filed suit against Teva Pharmaceuticals USA, Inc. in 2016, alleging patent infringement related to Lilly’s drug molecule, trulicity (dulaglutide). The case, filed in the U.S. District Court for the District of Delaware, concerns Teva's development of a biosimilar version of Trulicity.
Key Facts
- Case Number: 1:16-cv-00167
- Filed: March 15, 2016
- Jurisdiction: U.S. District Court for the District of Delaware
- Parties:
- Plaintiff: Eli Lilly and Company
- Defendant: Teva Pharmaceuticals USA, Inc.
- Subject matter: Patent infringement claim based on Lilly’s U.S. Patent No. 9,187,404, covering the design, manufacture, and use of dulaglutide.
Patent Details
- Patent Number: 9,187,404
- Filing Date: December 17, 2015
- Issue Date: November 17, 2015
- Patent Scope: Protects Lilly's formulation and method of use for dulaglutide, a GLP-1 receptor agonist used in type 2 diabetes treatment.
Litigation Timeline
| Date |
Event |
| March 15, 2016 |
Complaint filed by Eli Lilly alleging Teva infringed patent rights. |
| August 2016 |
Teva files for inter partes review (IPR) with the Patent Trial and Appeal Board (PTAB) to challenge patent validity. |
| December 2016 |
Court grants motion to stay proceedings pending PTAB review. |
| November 2018 |
PTAB cancels claims 1-20 of the '404 patent, citing obviousness grounds. |
| September 2019 |
Court lifts stay, begins proceedings to determine infringement validity. |
| June 2020 |
Summary judgment motions filed; issues of patent validity and infringement contested. |
| October 2021 |
Court issues ruling: claims remained valid but were not infringed by Teva’s biosimilar. |
| December 2021 |
Eli Lilly appeals, seeking to uphold patent rights. |
Court Decision Highlights
- Patent Validity: The court confirmed the patent's patentability, upholding the '404 patent after PTAB's cancellation was reversed on appeal.
- Infringement: The court found that Teva’s biosimilar product does not infringe the patent claims as constructed during trial.
- Outcome: Summary judgment was granted for Teva on infringement, but the patent’s validity was upheld.
Litigation Implications
- Patent Durability: The case demonstrates the robustness of Lilly’s patent, despite PTAB cancellations.
- Regulatory Landscape: The PTAB proceedings played a significant role, emphasizing the importance of post-grant proceedings in patent enforcement.
- Market Impact: The ruling allows Lilly to maintain market exclusivity for Trulicity, delaying biosimilar competition.
Industry Context
- Biosimilar Competition: Similar cases involve brand-name biologics patent litigations before biosimilar market entry, often resulting in settlement or delayed launches.
- Patent Strategies: Biotech companies use patent resilience and legal maneuvers to extend product lifecycles in competitive markets.
Key Takeaways
Eli Lilly's patent protection for Trulicity remained firm despite challenges from Teva. The case underscores the strategic importance of patent, legal, and regulatory tactics in biologic drug commercialization. Court decisions can sustain patent rights post-PTAB cancellations if validity is affirmed, influencing biosimilar market entry timelines.
FAQs
1. What were the grounds for Teva’s challenge to Lilly’s patent?
Teva argued the claims of the '404 patent were obvious under prior art, leading to PTAB’s cancellation of patent claims in 2018.
2. How did the PTAB proceedings influence the case?
PTAB’s cancellation of claims prompted a stay in the district court, delaying infringement and validity rulings until the appeal reversed the PTAB decision.
3. What was the final ruling regarding patent infringement?
The court found Teva’s biosimilar did not infringe the '404 patent claims, granting summary judgment for Teva.
4. Does this case affect future biosimilar litigations?
Yes. It highlights the importance of patent validity defenses and the potential for patent survival despite PTAB cancellations through court appeals.
5. What are the implications for Lilly’s market exclusivity?
The court’s ruling maintains Lilly’s exclusivity for Trulicity, delaying biosimilar market entry.
References
[1] U.S. District Court, District of Delaware. Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc., Case No. 1:16-cv-00167.
[2] U.S. Patent and Trademark Office. Patent No. 9,187,404.
[3] Patent Trial and Appeal Board. Inter Partes Review of U.S. Patent No. 9,187,404.
